Tesofensine FAQ: common questions answered
An oral appetite drug with weight-loss trial results and heart-rate and psychiatric risks.
Also called: NS2330, NS-2330, NS 2330.
Fat-loss drugs · Serotonin, norepinephrine and dopamine reuptake inhibitor.
- Is Tesofensine FDA-approved? No FDA-approved product or label found. No tesofensine PCAC decision found. No 503B inclusion found; orphan designation is not approval.
- How do people take it? By mouth, once daily. 24 weeks. Source: studied in a trial.
- What's the difference between Tesofensine and Retatrutide? Tesofensine: an oral appetite drug with weight-loss trial results and heart-rate and psychiatric risks. Retatrutide: an experimental weekly injection with phase 3 weight-loss results. Why people pair them: users seek stronger appetite suppression or less food noise. No controlled stack trial was found.
- Can I take it with Retatrutide? Users seek stronger appetite suppression or less food noise. No controlled stack trial was found. Combined heart-rate and poor-intake risks are not quantified. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Yes, in competition (WADA 2026). Named on page 16. A long detection window does not define an athlete’s safe washout time.
- How do I store it once opened? No validated home-mixed liquid stability or beyond-use time found.
Related to Tesofensine
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- 5-amino-1MQ: An experimental NNMT blocker with animal findings, no human dosing trials and uncertain risks.
- SLU-PP-332: An exercise-mimicking research chemical with mouse benefits and no human dosing trials.
- AOD-9604: A growth-hormone fragment whose largest obesity trial failed to show meaningful weight loss.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Download medicine data, European Medicines Agency · European Medicines Agency · 2026
- METOPROLOL SUCCINATE tablet, extended release, DailyMed / National Library of Medicine · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Darmerica, LLC - 716152 - 12/08/2025, FDA · FDA · 2025
- Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial., Lancet (London, England) · 2013
- Under-reporting of adverse effects of tesofensine., Astrup A et al. · Lancet (London, England) · 2013
- About the ARTG Search Visualisation Tool, Therapeutic Goods Administration
- Drug Product Database online query, Health Canada
- Sertraline: an antidepressant medicine, NHS
- Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials., Yu H et al. · Obesity (Silver Spring, Md.) · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.